Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21(WAF1)

Current Biology

Volumn 7, Issue 1, 1997, Pages 71-80

  Ball, Kathryn L ^a   Lain, Sonia ^a   Fåhraeus, Robin ^a   Smythe, Carl ^a   Lane, David P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031025385     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(06)00029-7     Document Type: Article

References (57)

1. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991, 51:6304-6311.
2. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995, 92:8493-8497.
3. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53 dependent and independent pathways. Nature 1993, 362:849-852.
4. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993, 362:847-849.
5. Merritt AJ, Potten CS, Kemp CJ, Hickman J, Balmain A, Lane DP, Hal PA: The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994, 54:614-617.
6. Lu X, Lane DP: Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes. Cell 1993, 75:765-778.
7. Pietenpol JA, Tokino T, Thiagalingam S, El-Deiry W, Kinzler K, Vogelstein B: Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 1994, 91:1998-2002.
8. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al.: WAF-1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
9. Harper JW, Adami GR, Wei N, Keyomasi K, Elledge SJ: The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
10. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:701-704.
11. Gu Y, Turck CT, Morgan DO: Inhibition of Cdk2 activity in vivo by an associated 20K regulatory subunit. Nature 1993, 371:257-261.
12. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299.
13. Buckbinder L, Talbot R, Velasco-Miguel S, Takenaka I, Faha B, Siezinger BR, Kley N: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995, 377:646-649.
14. Kastan MB, Zhan Q, El-Deiry WK, Carrier F, Jacks T, Walsh WV, et al.: A mammalian cell cycle checkpoint pathway utilising p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992, 71:587-597.
15. Kearsey JM, Shivji MKK, Hal PA, Wood RD: Does the p53 up-regulated Gadd45 protein have a role in excision repair? Science 1995, 270:1004-1005.
16. Hollstein M, Sidransky D, Vogelstein B, Harris C: p53 mutations in human cancer. Science 1991, 253:49-53.
17. Lane DP: p53, guardian of the genome. Nature 1992, 358:15-16.
18. Momand J, Zambetti GP, Olson DC, Levine AJ: The mdm-2 oncogene product forms a complex with p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
19. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P: Mice lacking p21CIP1/WAF1 undergo normal development but are defective in G1 checkpoint control. Cell 1995, 82:675-684.
20. Waldman T, Kinzler KW, Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995, 55:5187-5190.
21. Halazonetis TD, Kandil AN: Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J 1993, 12:5057-5064.
22. Hupp TR, Meek DM, Midgley CA, Lane DP: Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res 1993, 21:3167-3174.
23. Hupp TR, Sparks A, Lane DP: Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995, 83:337-345.
24. Picksley SM, Vojtesek B, Sparks A, Lane DP: Immunochemical analysis of the interaction of p53 with MDM2: fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994, 9:2523-2529.
25. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme, TL, Yang G, et al.: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995, 55:5151-5155.
26. Chen J, Jackson PK, Kirschner MW, Dutta A: Separate domains of p21 involved in the inhibition of Cdk and PCNA. Nature 1995, 374:386-388.
27. Harper JW, Elledge SJ, Keyomasi K, Dynlacht B, Tsai L-H, Zhang P, et al.: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995, 6:387-400.
28. WAF1. Nature 1995, 375:159-161.
29. Nakanishi M, Robetorye R, Pereira-Smith O, Smith J: The C-terminal of p21SDI1/WAF1/CIP1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. J Biol Chem 1995, 270:17060-17063.
30. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993, 7:812-821.
31. Sherr C: G1 phase progression: cycling on cue. Cell 1994, 79:551-555.
32. DKN2/INK4A. Curr Biol 1996, 6:84-91.
33. Chen J, Saha P, Kornbluth S, Dynlacht BD, Dutta A: Cyclin-binding motifs are essential for the function of p21 Cip1. Mol Cell Biol 1996, 16:4673-4682.
34. WAF-1 gene activities. Mol Cell Biol 1996, 16:1786-1793.
35. Russo AA, Jeffrey PD, Patten AK Massague J, Pavletich NP: Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996, 382:325-331.
36. Goubin F, Ducommun B: Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor. Oncogene 1995, 10:2281-2287.
37. Nakanishi M, Robetorye RS, Adami GR, Pereira-Smith O, Smith J: Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1. EMBO J 1995, 14:555-563.
38. Chen IT, Akamatsu M, Smith ML, Lung FDT, Duba D, Roller PP, et al.: Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction. Oncogene 1996, 12:595-607.
39. WAF1 and proliferating cell nuclear antigen. Curr Biol 1995, 5:275-282.
40. WAF1. Eur J Biochem 1996, 237:854-861.
41. Li B, Tom JY, Oare D, Yen R, Fairbrother WJ, Wells JA, Cunningham BC: Minimization of a peptide hormone. Science 1995, 270:1657-21
42. Hal H, Williams EJ, Moore SE, Wash FS, Prochiantz A, Doherty P: Inhibition of FGF-stimulated phosphatidylinositol hydrolysis and neurite outgrowth by a cell-membrane permeable phosphopeptide. Curr Biol 1996, 6:580-587.
43. Lehman TA, Modali R, Boukamp P, Stanek J, Bennett WP, Welsh JA, et al.: p53 mutations in human immortalized epithelial cell lines. Carcinogenesis 1993, 14:833-839.
44. Powis G: Signalling targets for anticancer drug development. Trends Pharmacol Sci 1992, 12:188-194.
45. Gibbs JB, Oliff A: Pharmaceutical research in molecular oncology. Cell 1994, 79:193-198.
46. Gibbs JB, Oliff A, Kohl NE: Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994, 77:175-178.
47. Moodie SA, Wolfman A: The 3R's of life: Ras, Raf, and growth regulation. Trends Genef 1994, 10:44-48
48. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry M, et al.: Phospnatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527-532.
49. Pawson T, Schlessinger J: SH2 and SH3 domains. Curr Biol 1993, 3:434-432.
50. Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW, Schreiber SL: Structural basis for the binding of proline-rich peptides to SH3 domains. Cell 1994, 76:933-945.
51. Davies DR, Padlan EA, Sheriff S: Antibody-antigen complexes. Annu Rev Biochem 1990, 59:439-473.
52. de Vos AM, Ultsch M, Kossiakoff AA: Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992, 255:306-312.
53. Kelley RF, O'Connell MP: Thermodynamic analysis of an antibody functional epitope. Biochemistry 1993, 32:6828-6835.
54. Clackson T, Wells JA: A hot spot of binding energy in a hormone-receptor interface. Science 1995, 267:383-386.
55. Su J-Y, Rempel R, Erikson E, Mailer JL: Cloning and characterization of the Xenopus cyclin-dependent kinase inhibitor p21 Xic1. Proc Natl Acad Sci USA 1995, 92:10187-10191.
56. Zhang H, Hannon GJ, Beach D: p21-containing cyclin-dependent kinases exist in both active and inactive states. Genes Dev 1994, 8:1750-1758.
57. Renzing J, Hansen S, Lane DP: Oxidative stress is involved in the UV activation of p53. J Cell Sci 1996, 109:1105-1112.